Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer

Cancer Immunology, Immunotherapy · Published 2023-02-01 · Available online 4 Aug 2022 · Journal article · DOI 10.1007/s00262-022-03238-w · PMID: 35925286 · PMC · Cited by 56 (Crossref)

Authors (19)

Jiannan Chen, Jianhua Hu, Lili Gu, Feng Ji, Fan Zhang, Miaomiao Zhang, Jun Li, Zhengliang Chen, Longwei Jiang, Yan Zhang, Ruifang Shi, Lihua Ma, Shaochang Jia, Ying Zhang, Qi Zhang, Junqing Liang, Shunyu Yao, Zhigang Hu, Zhigang Guo

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Volume

72

Issue

2

Pages

409-425

Year

2023

Citation

Chen, J., Hu, J., Gu, L., et al. (2023). Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-022-03238-w

Related articles

• Integrated Engineering of CAR ‐T Cells for Solid Tumours · Cell Proliferation · 2026 · Cites or is cited by this article
• Stem cell engineering for the generation of allogeneic CAR-directed natural killer T cells targeting endometrial carcinoma · Experimental Hematology & Oncology · 2026 · Cites or is cited by this article
• Immunotherapy for gynecological tumors: From mechanism to clinical practice · Chinese Medical Journal · 2026 · Cites or is cited by this article
• Current state of CAR-T cell therapies for solid tumors · Med · 2026 · Cites or is cited by this article
• Ferroptosis in ovarian cancer: Regulation, immunity, and therapeutic potential with the tumor microenvironment · Seminars in Oncology · 2026 · Cites or is cited by this article
• HBO1 suppresses anti-tumor immunity of CD8⁺ T Cells in thyroid cancer by recruiting BRD4 to regulate VTCN1 expression · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Conserved minimal CD8 cytotoxic immune-state unit in an IL18R1-associated immune program in hepatocellular carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Impact of neck nodal yield on immune checkpoint inhibitor outcome after recurrence in head and neck squamous cell carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Preclinical efficacy of iPSC-derived MUC1-targeted CAR-NK cells against esophageal squamous cell carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal
• Survival outcomes of conversion curative therapy following atezolizumab–bevacizumab in advanced hepatocellular carcinoma · Cancer Immunology, Immunotherapy · 2026 · Same journal

Metrics

Citations (Crossref)

56